GSK’s (GSK) “Hold” Rating Reiterated at Deutsche Bank Aktiengesellschaft

GSK (LON:GSK)‘s stock had its “hold” rating restated by equities research analysts at Deutsche Bank Aktiengesellschaft in a note issued to investors on Tuesday, Digital Look reports. They currently have a GBX 2,000 price target on the stock. Deutsche Bank Aktiengesellschaft’s price target would suggest a potential upside of 7.61% from the company’s current price.

A number of other equities research analysts have also recently issued reports on GSK. Jefferies Financial Group reiterated a “buy” rating and set a GBX 2,500 price objective on shares of GSK in a research note on Wednesday, July 29th. Berenberg Bank raised their price objective on shares of GSK from GBX 2,000 to GBX 2,200 and gave the stock a “hold” rating in a research report on Tuesday. Finally, Royal Bank Of Canada reissued a “sector perform” rating and set a GBX 1,975 target price on shares of GSK in a report on Tuesday, September 8th. Two investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of GBX 2,064.38.

GSK Trading Up 0.2%

Shares of GSK opened at GBX 1,858.50 on Tuesday. GSK has a 52-week low of GBX 1,455 and a 52-week high of GBX 2,282. The company has a market cap of £74.47 billion, a price-to-earnings ratio of 15.78, a PEG ratio of 1.24 and a beta of 0.29. The company has a debt-to-equity ratio of 103.36, a quick ratio of 0.73 and a current ratio of 0.82. The stock has a fifty day moving average price of GBX 1,899.20 and a two-hundred day moving average price of GBX 1,964.02.

GSK (LON:GSK) last posted its quarterly earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. Analysts predict that GSK will post 175.980975 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Jeannie Lee bought 802 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The stock was acquired at an average cost of GBX 5,069 per share, with a total value of £40,653.38. Also, insider Jonathan Symonds acquired 1,550 shares of the stock in a transaction on Friday, June 19th. The shares were acquired at an average price of GBX 1,935 per share, for a total transaction of £29,992.50. Insiders bought 3,625 shares of company stock valued at $13,494,563 over the last quarter. Insiders own 0.20% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.